Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifitegrast in Dry Eye Disease
NCT06879782Phase 3Recruiting
- Sponsor
- Lunan Better Pharmaceutical Co., Ltd.
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye disease (DED) comparing Lifitegrast with Placebo (2 arms). Primary endpoints: Inferior Corneal Fluorescein Staining Score at Day 84 and Eye Dryness Score at Day 84. Started Mar 2024; status: recruiting.
02
Drugs
lifitegrast
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06879782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06879782.